Chemomab Therapeutics Ltd. (NASDAQ: CMMB)
$1.6600
-0.0200 ( -1.19% ) 38.1K
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Market Data
Open
$1.6600
Previous close
$1.6800
Volume
38.1K
Market cap
$31.11M
Day range
$1.6200 - $1.7000
52 week range
$0.4500 - $2.5500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Form 6-K | 1 | Nov 18, 2024 |
6-k | Form 6-K | 3 | Nov 14, 2024 |
6-k | Form 6-K | 6 | Oct 11, 2024 |
6-k | Form 6-K | 31 | Aug 21, 2024 |
6-k | Form 6-K | 30 | Jul 25, 2024 |
6-k | Form 6-K | 1 | Jun 12, 2024 |
6-k | Form 6-K | 3 | May 09, 2024 |
6-k | Form 6-K | 3 | May 08, 2024 |
6-k | Form 6-K | 5 | May 03, 2024 |
20-f | Annual reports | 97 | Mar 28, 2024 |